Image

U.S. Cancer Treatment Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

U.S. Cancer Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • Country Level
  • 350 Pages
  • No of Tables: 76
  • No of Figures: 31

U.S. Cancer Treatment Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 86,942.10 USD Million
Diagram Market Size (Forecast Year) USD 223,234.64 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

U.S. Cancer Treatment Market, By Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics), Country (U.S.) - Industry Trends and Forecast  to 2029

Market Analysis and Insights: U.S. Cancer Treatment Market

The U.S. cancer treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.8% in the forecast period of 2022 to 2029 and is expected to reach USD 223,234.64 million by 2029 from USD 86,942.10 million in 2021. The high prevalence of cancer and increasing R&D activities for its effective application are likely to be the major drivers that propel the market's demand in the forecast period.

Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor. This process is called metastases. The cancerous tumor is also referred to as a malignant tumor. The benign tumor does not invade nearby tissues, and when removed, benign tumors usually don't grow back, whereas cancerous tumors sometimes do.

There are more than a hundred types of cancer. Some categories of cancers that begin in specific types of cells include carcinoma, sarcoma, leukemia, lymphoma, and multiple myeloma, among others. Based on the type of cancer, many types of cancer treatments are available. Cancer treatment includes biomarker testing for cancer treatment, chemotherapy, hormone therapy, hyperthermia, immunotherapy, photodynamic therapy, radiation therapy, surgery, stem cell transplant, and targeted therapies.

According to GLOBOCAN, 19,292,789 new cancer cases were found in 2020 worldwide. The highest cases of breast cancer were found. Therefore, the high prevalence of cancer, initiatives taken by the government for awareness and early detection of cancer, and ongoing clinical trials are expected to fuel the market's growth. The cancer burden in the region and the rise in awareness initiatives taken by various organizations are expected to act as a driver for the growth of the market. However, the high cost of cancer treatment may restrain the market growth. The presence of big market players in the region is expected to act as an opportunity for the market's growth. However, the side effects of drugs may challenge the market's growth.

The U.S. cancer treatment market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

U.S. Cancer Treatment Market

U.S. Cancer Treatment Market Scope and Market Size

The U.S. cancer treatment market is categorized into four notable segments based on cancer type, treatment, route of administration, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of cancer type, the U.S. cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma. In 2022, the breast cancer segment is expected to dominate the market because of the high prevalence of breast cancer.
  • On the basis of treatment, the U.S. cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others. In 2022, the medication segment is expected to dominate the market because of increasing FDA approvals of cancer drugs in the region.
  • On the basis of route of administration, the U.S. cancer treatment market is segmented into injectable, oral, and others. In 2022, the injectable segment is expected to dominate the market because of the easy availability of cancer treatment in injectable form.
  • On the basis of end user, the U.S. cancer treatment market is segmented into hospitals and specialty clinics. In 2022, the hospitals segment is expected to dominate the market due to the presence of large hospitals in the country offering advanced cancer treatment.

U.S. Cancer Treatment Market Country Level Analysis

The U.S. cancer treatment market is analyzed, and market size information is provided by country, cancer type, treatment, route of administration, and end user.

The U.S. is expected to grow due to big market players present in the region. The players are launching advanced cancer treatment medications for the patients.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of U.S. brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the U.S. Cancer Treatment Market

The U.S. cancer treatment market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the dental instruments market. The data is available for the historical period 2011 to 2020.

Competitive Landscape and U.S. Cancer Treatment Market Share Analysis

The U.S. cancer treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the U.S. cancer treatment market.

Some of the major companies in the U.S. cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for cancer treatment are bridging the gap for various treatments.

For instance,

  • In October 2021, Novartis AG announced that it had received FDA approval for its Scemblix (asciminib) to treat chronic myeloid leukemia (CML). This will help the company to increase its revenue

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the cancer treatment market, which also benefits the organization to improve their offering for the U.S. cancer treatment market.

 


SKU-

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 PREVALENCE OF CANCER, BY AGE, 2016-17, (BY COUNTRY)

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 7 U.S. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 8 U.S. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 U.S. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 10 U.S. COLORECTAL CANCER WITH METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 U.S. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 U.S. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 U.S. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 U.S. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 U.S. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 U.S. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 17 U.S. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 U.S. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 19 U.S. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 U.S. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 U.S. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 U.S. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 U.S. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 U.S. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 U.S. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 U.S. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 U.S. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 U.S. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 U.S. PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 U.S. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 U.S. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 U.S. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 U.S. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 34 U.S. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 U.S. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 U.S. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 U.S. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 U.S. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 39 U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 40 U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 42 U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 U.S. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 U.S. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 U.S. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 U.S. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 U.S. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 U.S. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 U.S. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 U.S. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 U.S. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 U.S. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 U.S. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 U.S. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 U.S. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 U.S. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 U.S. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 U.S. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 U.S. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 60 U.S. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 61 U.S. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 62 U.S. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 63 U.S. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 64 U.S. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 U.S. PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 U.S. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 U.S. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 U.S. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 U.S. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 U.S. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 U.S. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 U.S. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 U.S. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 U.S. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials